CDDO-Im
CAT:
804-HY-15725-06
Size:
100 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No
CDDO-Im
- CAS Number: 443104-02-7
- UNSPSC Description: CDDO-Im (RTA-403) is an activator of Nrf2 and PPAR, with Kis of 232 and 344 nM for PPARα and PPARγ[1][2].
- Target Antigen: Ferroptosis; Keap1-Nrf2; PPAR
- Type: Reference compound
- Related Pathways: Apoptosis;Cell Cycle/DNA Damage;Metabolic Enzyme/Protease;NF-κB;Vitamin D Related/Nuclear Receptor
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Assay Protocol: https://www.medchemexpress.com/CDDO-Im.html
- Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)
- Smiles: CC(C)([C@]1([H])CC[C@@]([C@@]2(CC[C@]3(CCC(C)(C[C@@]3([H])[C@]24[H])C)C(N5C=CN=C5)=O)C)6C)C(C(C#N)=C[C@]1(C)C6=CC4=O)=O
- Molecular Weight: 541.72
- References & Citations: [1]Place AE, et al. The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res. 2003 Jul;9(7):2798-806.|[2]Liby K, et al. The synthetic triterpenoids, CDDO and CDDO-imidazolide, are potent inducers of heme oxygenase-1 and Nrf2/ARE signaling. Cancer Res. 2005 Jun 1;65(11):4789-98.|[3]So JY, et al. A synthetic triterpenoid CDDO-Im inhibits tumorsphere formation by regulating stem cell signaling pathways in triple-negative breast cancer. PLoS One. 2014 Sep 17;9(9):e107616.
- Shipping Conditions: Room Temperature
- Clinical Information: No Development Reported